InflaRx (IFRX) EBITDA Margin Growth (1y) (2019 - 2026)
InflaRx (IFRX) EBITDA Margin Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7,666.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,238.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2,002.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3,558.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,091.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -1,651.00 |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.65 Mn |
| Dec 31, 2025 | -839.00 |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | 20.94 Mn |
| Mar 31, 2025 | -143,311.00 |
| Dec 31, 2024 | 11,151.00 |
| Sep 30, 2024 | -1.24 Mn |
| Jun 30, 2024 | -24.28 Mn |
| Mar 31, 2024 | -3.47 Mn |
| Dec 31, 2023 | 228,444.00 |
| Sep 30, 2023 | -129,100.00 |
| Jun 30, 2023 | 60,045.00 |
| Mar 31, 2023 | -178,536.00 |
| Dec 31, 2022 | -231,432.00 |
| Sep 30, 2022 | -61,475.00 |
| Jun 30, 2022 | 9,269.00 |
| Mar 31, 2022 | 134,407.00 |
| Dec 31, 2021 | 40.00 |
| Sep 30, 2021 | 139.39 Bn |
| Jun 30, 2021 | -148,198.00 |